Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified-release tacrolimus conversion in stable pediatric liver transplant recipients
2015-001076-22Phase 2
- Sponsor
- Fujisawa Pharmaceutical
- Start
- Apr 2015
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in Hepatic transplant rejection (LTR), sponsored by Fujisawa Pharmaceutical. Primary endpoints: Cmin and AUC0-24.
02
Drugs
tacrolimus
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on 2015-001076-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001076-22.